Korneuburg, Austria, April 13, 2026 Marinomed Biotech AG (“Company”) has successfully
completed the capital increase against cash contribution announced on March 19, 2026.
Through the rights offering to existing shareholders (the “Rights Offering”), 33,322 new shares
were subscribed for by exercising subscription rights. Shares not subscribed for were
subsequently offered in a prospectus-free private placement at a subscription price of EUR
14 per new share. An additional 125,717 new shares were placed within this framework.
The full press release is available as download here: